

269~274. hSulf-1过表达提高乳腺癌MCF-7细胞对PARP抑制剂AZD2281的敏感性[J]. 徐高亚, 季卫丹, 严妍, 包龙龙, 沈舒文, 顾蕾, 傅晓辉, 姜小清, 苏长青, 吴孟超. 中国肿瘤生物治疗杂志, 2014, 21(3)

hSulf-1过表达提高乳腺癌MCF-7细胞对PARP抑制剂AZD2281的敏感性 [点此下载全文](#)

[徐高亚](#) [季卫丹](#) [严妍](#) [包龙龙](#) [沈舒文](#) [顾蕾](#) [傅晓辉](#) [姜小清](#) [苏长青](#) [吴孟超](#)

苏州大学 基础医学与生物科学学院 病原生物学系, 江苏 苏州 215123; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438; 苏州大学 基础医学与生物科学学院 病原生物学系, 江苏 苏州 215123; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438; 第二军医大学 东方肝胆外科医院 国家肝癌研究中心 分子肿瘤研究室, 上海 200438

基金项目: 国家自然科学基金资助项目 (No. 81370552, No. 81172303, No. 81172019)

DOI: 10.3872/j.issn.1007-385X.2014.03.006

摘要:

探讨人硫酸酯酶-1 (human sulfatase 1, hSulf-1) 基因过表达是否提高乳腺癌MCF-7细胞对PARP抑制剂AZD2281的敏感性。方法: 采用不同浓度AZD2281处理细胞, 并筛选AZD2281处理的最佳浓度。将携hSulf-1基因的重组腺病毒Ad5-hSulf1感染MCF-7细胞, 以Ad-hSulf1和AZD2281单独或联合处理MCF-7细胞, 以Ad5-EGFP处理为对照。采用流式细胞术检测细胞周期, 克隆形成实验检测细胞克隆形成率, Western blotting检测细胞周期蛋白依赖性激酶4 (cyclin dependent kinase 4, CDK4) 及磷酸化蛋白激酶B (phosphorylated protein kinase B, p-AKT) 的表达, Transwell法、MTT法分别检测细胞的迁移及增殖。结果: AZD2281浓度为7 $\mu\text{mol/L}$ 时对MCF-7细胞的抑制作用趋于峰值, 用于后续实验。Ad5-hSulf1+AZD2281联合处理与AZD2281单独处理相比, MCF-7细胞的G2/M期细胞比例明显增多[(22.15 \pm 0.17)% vs (17.44 \pm 0.57)% , P<0.01], 细胞克隆形成率[(21.43 \pm 1.52)% vs (49.43 \pm 1.44)% , P<0.01]及细胞周期蛋白CDK4的表达[(0.67 \pm 0.02) vs (0.72 \pm 0.02) , P<0.05], AKT的磷酸化水平[(0.17 \pm 0.003) vs (0.42 \pm 0.02) , P<0.01]均明显降低, 同时细胞的增殖率和迁移能力也有明显下降[(57.69 \pm 4.83)% vs (79.35 \pm 5.44)% ; (10.33 \pm 1.53)个 vs (50.67 \pm 2.31)个, 均P<0.01]。结论: hSulf-1过表达可明显提高乳腺癌细胞MCF-7对AZD2281的化疗敏感性, 阻滞细胞周期于G2/M期, 并更明显地抑制乳腺癌细胞的增殖和迁移能力, 这一效应可能是通过调节细胞周期蛋白CDK4及AKT通路产生的。

关键词: [硫酸酯酶-1基因](#) [乳腺癌](#) [MCF-7细胞](#) [周期蛋白](#) [增殖](#) [迁移](#) [化疗敏感性](#)

hSulf-1 overexpression enhance the sensitivity of breast cancer MCF-7 cells to the PARP inhibitor AZD2281 [Download Fulltext](#)

[Xu Gaoya](#) [Ji Weidan](#) [Yan Yan](#) [Bao Longlong](#) [Shen Shuwen](#) [Gu Lei](#) [Fu Xiaohui](#) [Jiang Xiaoqing](#) [Su Changqing](#) [Wu Mengchao](#)

Department of Pathogen Biology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou 215123, Jiangsu, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China; Department of Pathogen Biology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou 215123, Jiangsu, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China; Department of Molecular Oncology, Eastern Hepatobiliary Surgery Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China

Fund Project: Project supported by the National Natural Scientific Foundation of China (No. 81370552, No. 81172303, No. 81172019)

Abstract:

To investigate the possibility of enhance the sensitivity of breast cancer MCF-7 cells to the PARP inhibitor AZD2281 by up-regulate the expression of hSulf-1. Methods: MCF-7 cells were infected with Ad5-hSulf1 or Ad5-EGFP. Transfectants were treated with different concentrations of AZD2281 and the most optimal concentration was determined. In further experiments, both Ad5-hSulf-1-overexpressing MCF-7 cells and Ad5-EGFP-expressing control MCF-7 cells were treated with AZD2281 at the optimal concentration determined. After treatment for 24 h, cell cycle progression was assessed by flow cytometry (FCM), formation ability of MCF-7 cells by colony formation assay, protein levels of cyclin dependent kinase 4 (CDK4) and phosphorylated protein kinase B (p-AKT) Western blotting, cell migration by Transwell assay, and proliferative ability by MTT assay. Results: AZD2281 showed the peak inhibitory activity at a concentration of 7 $\mu\text{mol/L}$. When this concentration was used, Ad5-EGFP-expressing MCF-7 cells showed significant increased in the proportion of G2/M phase cells [(22.15 \pm 0.17)% vs [17.44 \pm 0.57)% , P<0.01], the colony formation ability [(21.43 \pm 1.52)% vs [49.43 \pm 1.44)% , P<0.01], levels of cell cycle protein CDK4 [(0.67 \pm 0.02 vs 0.72 \pm 0.02) , P<0.01] and p-AKT [(0.17 \pm 0.003 vs 0.42 \pm 0.02) , P<0.01], and the rate of migration [(57.69 \pm 4.83)% vs [79.35 \pm 5.44)% , P<0.01] and proliferation [(10.33 \pm 1.53 vs 50.67 \pm 2.31) , P<0.01], as compared with MCF-7 cells expression Ad5-hSulf-1. Conclusion: The overexpression of hSulf-1 may significantly increase the chemosensitivity of MCF-7 cells to AZD2281, induce cell cycle arrest at G2/M-phase and inhibit cell proliferation and migration capacities, possibly through regulation of CDK4 expression and AKT phosphorylation.

Keywords: [human sulfatase-1 \(hSulf-1\) gene](#) [breast cancer](#) [MCF-7 cell](#) [cycle protein](#) [proliferation](#) [migration](#) [chemosensitivity](#)

